Researchers showed that 1.34 mg of Fotivda provided decreased tumor size and may be more tolerable than an 0.89-mg dose among patients with renal cell carcinoma.

GU ASCO annual meeting featured a kidney cancer trials in progress session and a presentation by Dr. Eric Jonasch discussing a phase 1b/2 study of combination 177Lu girentuximab + cabozantinib and ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...

Cells in the body have to move around in order to do their jobs. During development, for instance, cells are distributed to ...

INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a ...

Uscreen, a video monetization platform for the creator economy, today announced a $150 million investment with PSG, a leading growth equity firm that specializes in partnering with software and ...

Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...

A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.

Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.